Compare LYNX & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYNX | SLBT |
|---|---|---|
| Founded | N/A | N/A |
| Country | | Taiwan |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2026 | 2025 |
| Metric | LYNX | SLBT |
|---|---|---|
| Price | $13.59 | $1.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 434.0K | 77.8K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.21 | $1.74 |
| 52 Week High | $14.10 | $6.25 |
| Indicator | LYNX | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 29.95 |
| Support Level | $12.21 | N/A |
| Resistance Level | N/A | $3.36 |
| Average True Range (ATR) | 0.77 | 0.27 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 81.48 | 1.25 |
Lyntris Inc is a defense technology company that develops connectivity solutions for military applications. Its products consist of interconnected subsystems designed to support defense and military customers in detecting threats, making decisions, and responding to operational requirements across multi-domain environments. The company serves U.S. and allied nation military customers. Its solutions are deployed across three core missions: Maritime Domain Awareness; Air & Missile Defense; and Space ISR & Resilient Communications. Maximum revenue is derived from the Maritime Domain Awareness business, which includes solutions focused on maritime monitoring, tracking and analysis that support government and defense customers in maintaining situational awareness across maritime environments.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.